Literature DB >> 9172002

Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes.

A Greco1, C Miranda, S Pagliardini, L Fusetti, I Bongarzone, M A Pierotti.   

Abstract

The NTRK1 gene in the q arm of chromosome 1 encodes one of the receptors for the nerve growth factor and is frequently activated as an oncogene in papillary thyroid carcinomas. The activation is due to chromosomal rearrangements juxtaposing the NTRK1 tyrosine kinase domain to 5'-end sequences from different genes. The thyroid TRK oncogenes are activated by recombination with at least three different genes: the gene coding for tropomyosin and TPR, both on chromosome 1,and TFG on chromosome 3. In a previous study, we showed that two tumors carrying the TPR/NTRK1 rearrangement contained structurally different oncogenes named TRK-T1 and TRK-T2. In this paper, we report (1) the cDNA structure of TRK-T2, (2) evidence that TRK-T2 is generated by different rearrangements in two thyroid tumors, and (3) a detailed analysis of the three different TPR/NTRK1 rearrangements. With molecular studies based on Southern blot hybridization, cloning, and sequencing, we show that all the rearrangements are nearly balanced, involving deletion, insertion, or duplication of only few nucleotides. In one case, an additional rearrangement involving sequences derived from chromosome 17 was detected.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9172002

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  27 in total

1.  TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor.

Authors:  J C Arevalo; B Conde; B L Hempstead; M V Chao; D Martin-Zanca; P Perez
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

2.  TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Authors:  Jamie L Croucher; Radhika Iyer; Nanxin Li; Valentina Molteni; Jon Loren; W Perry Gordon; Tove Tuntland; Bo Liu; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-14       Impact factor: 3.333

3.  Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas.

Authors:  Liliána Z Fehér; Gábor Pocsay; László Krenács; Agnes Zvara; Enikő Bagdi; Réka Pocsay; Géza Lukács; Ferenc Győry; Andrea Gazdag; Erzsébet Tarkó; László G Puskás
Journal:  Pathol Oncol Res       Date:  2011-12-11       Impact factor: 3.201

4.  Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Authors:  Alan Charest; Vicky Kheifets; Julie Park; Keara Lane; Kevin McMahon; Cathy L Nutt; David Housman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

5.  AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

Authors:  Radhika Iyer; Carly R Varela; Jane E Minturn; Ruth Ho; Anisha M Simpson; Jennifer E Light; Audrey E Evans; Huaqing Zhao; Kenneth Thress; Jeffrey L Brown; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

Review 6.  Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.

Authors:  Eamon M Berge; Robert C Doebele
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

7.  The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.

Authors:  Elena Ardini; Roberta Bosotti; Andrea Lombardi Borgia; Cristina De Ponti; Alessio Somaschini; Rosaria Cammarota; Nadia Amboldi; Laura Raddrizzani; Andrea Milani; Paola Magnaghi; Dario Ballinari; Daniele Casero; Fabio Gasparri; Patrizia Banfi; Nilla Avanzi; Maria B Saccardo; Rachele Alzani; Tiziano Bandiera; Eduard Felder; Daniele Donati; Enrico Pesenti; Andrea Sartore-Bianchi; Marcello Gambacorta; Marco A Pierotti; Salvatore Siena; Silvio Veronese; Arturo Galvani; Antonella Isacchi
Journal:  Mol Oncol       Date:  2014-06-12       Impact factor: 6.603

8.  Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer.

Authors:  Aria Vaishnavi; Michael T Scherzer; Conan G Kinsey; Gennie L Parkman; Amanda Truong; Phaedra Ghazi; Sophia Schuman; Benjamin Battistone; Ignacio Garrido-Laguna; Martin McMahon
Journal:  Cell Rep       Date:  2020-08-04       Impact factor: 9.423

Review 9.  Nuclear pore proteins and cancer.

Authors:  Songli Xu; Maureen A Powers
Journal:  Semin Cell Dev Biol       Date:  2009-03-18       Impact factor: 7.727

10.  Molecular detection of PPAR gamma rearrangements and thyroid carcinoma in preoperative fine-needle aspiration biopsies.

Authors:  Christopher A French; Jonathan A Fletcher; Edmund S Cibas; Christopher Caulfield; Paulette Allard; Todd G Kroll
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.